PRTA Overview
Upcoming Projects (PRTA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PRTA)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (PRTA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PRTA)
-
Phase 1b Clinical Trial Results Of Prothena's (PRTA) PRX002/RG7935 For Parkinson's Disease Published In JAMA Neurology
Ticker: PRTA
Occurred on: Jun 19, 2018 -
Phase 3 VITAL study results for NEOD001 in newly diagnosed patients with AL Amyloidosis in cardiac dysfunction. - Discontinued
Ticker: PRTA
Occurred on: Apr 23, 2018 -
Prothena (PRTA) Phase 2 MAD Study testing PRX002 and RG7935 in Parkinson's Disease set for 2017 Q2 initiation
Ticker: PRTA
Occurred on: Jul 05, 2017 -
Prothena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting
Ticker: PRTA
Occurred on: Mar 06, 2016 -
Prothena Announces Appointment of Chief Commercial Officer
Ticker: PRTA
Occurred on: Feb 24, 2016
Strategic Initiatives (PRTA)
-
Prothena (PRTA) Announces Bristol Myers Squibb (BMY) Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Tickers: PRTA, BMY
Announcement Date: Jun 24, 2021
